Because human cancers with a higher tumor mutational burden are more likely to respond to immune checkpoint inhibition22–24, we tested the efficacy of RT and an antibody targeting PD-1 in a high mutational load mouse model of undifferentiated pleomorphic sarcoma (UPS)17. This evidence concerns the gene PDCD1 and undifferentiated pleomorphic sarcoma.